C.Q. Pharmaceutical Holding Co., Ltd. (SHE:000950)

SHE:000950 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	80,562	79,852	67,657	62,354	45,104
Other Revenue	-	266.8	171.83	166.87	115.37
Revenue	80,562	80,119	67,829	62,521	45,220
Revenue Growth (YoY)	0.55%	18.12%	8.49%	38.26%	33.61%
Cost of Revenue	74,573	73,841	62,038	56,817	41,012
Gross Profit	5,989	6,278	5,791	5,703	4,207
Selling, General & Admin	3,984	3,678	3,298	3,078	2,218
Research & Development	0.32	0.38	3.24	10.04	2.67
Other Operating Expenses	163.29	212.55	188.63	155.73	123.62
Operating Expenses	4,148	4,279	3,614	3,526	2,446
Operating Income	1,841	1,999	2,177	2,177	1,762
Interest Expense	-	-1,340	-1,123	-1,106	-675.52
Interest & Investment Income	402.41	393.27	355.29	347.92	325.03
Currency Exchange Gain (Loss)	-	0.18	0.44	-0.1	0.43
Other Non Operating Income (Expenses)	-1,613	-103.03	-12.36	3.66	-104.4
EBT Excluding Unusual Items	630.03	949.17	1,397	1,423	1,307
Impairment of Goodwill	-	-20.48	-27.91	-10.32	-14.68
Gain (Loss) on Sale of Investments	6.92	16.16	2.32	126.88	17.45
Gain (Loss) on Sale of Assets	10.53	0.79	10.05	3.52	21.54
Asset Writedown	-89.97	-0.01	-0.02	-0.35	-
Other Unusual Items	-	62.91	91.25	37.35	42.89
Pretax Income	557.51	1,009	1,472	1,580	1,374
Income Tax Expense	155.72	236.04	309.5	289.61	227.07
Earnings From Continuing Operations	401.79	772.5	1,163	1,291	1,147
Net Income to Company	401.79	772.5	1,163	1,291	1,147
Minority Interest in Earnings	-118.8	-117.54	-210.72	-285.23	-263.05
Net Income	282.99	654.96	952.28	1,005	884.34
Net Income to Common	282.99	654.96	952.28	1,005	884.34
Net Income Growth	-56.79%	-31.22%	-5.29%	13.69%	12.22%
Shares Outstanding (Basic)	1,769	1,724	1,731	1,734	1,728
Shares Outstanding (Diluted)	1,769	1,724	1,731	1,734	1,728
Shares Change (YoY)	2.62%	-0.45%	-0.12%	0.31%	-
EPS (Basic)	0.16	0.38	0.55	0.58	0.51
EPS (Diluted)	0.16	0.38	0.55	0.58	0.51
EPS Growth	-57.89%	-30.91%	-5.17%	13.73%	11.85%
Free Cash Flow	-437.27	264.13	17.76	-239.38	253.82
Free Cash Flow Per Share	-0.25	0.15	0.01	-0.14	0.15
Dividend Per Share	-	0.050	0.060	0.105	-
Dividend Growth	-	-16.67%	-42.86%	-	-
Gross Margin	7.43%	7.83%	8.54%	9.12%	9.30%
Operating Margin	2.28%	2.50%	3.21%	3.48%	3.90%
Profit Margin	0.35%	0.82%	1.40%	1.61%	1.96%
Free Cash Flow Margin	-0.54%	0.33%	0.03%	-0.38%	0.56%
EBITDA	2,105	2,224	2,408	2,346	1,886
EBITDA Margin	2.61%	2.78%	3.55%	3.75%	4.17%
D&A For EBITDA	263.52	225.25	231.17	169.06	124.75
EBIT	1,841	1,999	2,177	2,177	1,762
EBIT Margin	2.28%	2.50%	3.21%	3.48%	3.90%
Effective Tax Rate	27.93%	23.40%	21.02%	18.33%	16.52%
Revenue as Reported	-	80,119	67,829	62,521	45,220
Advertising Expenses	-	9.57	20.39	23.49	14.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.